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Wear and Tear Vision
Konrad P. Weber, MD, Caterina Schweier, MD, Veronika Kana, MD, PhD,
Thomas Guggi, MD, Katarzyna Byber, MD, Klara Landau, MD, FEBO
Dr. Weber:
A 66-year-old woman was referred to the neuro-ophthalmology unit with a 4-month history of insidi-
ous unexplained bilateral visual loss. Ophthalmologic
examination revealed visual acuity of ﬁnger counting in both
eyes. Confrontation visual ﬁeld testing demonstrated bilat-
eral central scotomas with relative sparing of the peripheral
ﬁelds. There was a mild right relative afferent pupillary
defect. The optic discs and macule appeared normal. Spe-
ciﬁcally, there was no optic disc pallor or swelling.
The patient’s medical history was signiﬁcant for coronary
artery disease associated with myocardial hypertrophy and
for treated secondary hypothyroidism after a subtotal thy-
roidectomy for benign nodular disease at age 44 years. Pre-
vious surgeries included bilateral hip replacements with
revision on the left side 1.5 years before consultation and
a right carotid endarterectomy for a 95% stenosis 3 months
before consultation. Ophthalmologic history revealed laser
photocoagulation for a retinal tear in her right eye. Review
of systems revealed recurrent depression, fatigue, and
a decrease in appetite with weight loss of about 10 kg.
The patient also indicated that for about 3 months, she
had paresthesias in her hands and feet, problems with bal-
ance, and bilateral hearing loss. She was a smoker of 10
pack-years.
At the time we examined the patient, she had already
undergone brain magnetic resonance imaging (MRI), which
did not reveal an explanation for her visual loss. We
performed orbital MRI, with both unenhanced and
contrast-enhanced sequences that showed no abnormalities
either. Based on the clinical ﬁndings of profound bilateral
visual loss for 4 months associated with bilateral central
scotomas and a normal fundus examination, normal neuro-
imaging, and signiﬁcant constitutional symptoms, we
suspected that the patient had paraneoplastic retinopathy,
such as cancer-associated retinopathy (CAR) or melanoma-
associated retinopathy (MAR). A full-ﬁeld electroretino-
gram (ERG) according to ISCEVstandards revealed severe
cone dysfunction (amplitude of single ﬂash b-wave and 30-
Hz ﬂicker response reduced to 20%–30% of the normal
mean) and low normal rod function (amplitude of the b-
wave reduced to 30%–40% of the normal mean).
Dr. Landau:
In view of the ERG ﬁndings that seemed to be consistent
with a paraneoplastic retinopathy, we referred the patient
for a systemic evaluation.
Dr. Weber:
An extensive workup revealed no evidence of malignancy.
In addition, an assay for antirecoverin antibodies for CAR
was negative, as were assays for a variety of anti-central
nervous system antibodies, including Hu, Ri, Yo, Amphi-
physin, CV2, Ta/Ma2, and Ma. A complete blood count
was normal except for polycythemia with hemoglobin of
185 g/L (normal: 117–153 g/L). Serum vitamin B12 con-
centration was normal. The erythrocyte sedimentation rate
was 2 mm/h, and autoimmune screening including ANA,
ANCA, anti-SS-A, and anti-SS-B revealed no abnormalities.
Both gynecologic and dermatologic examinations were non-
revealing. A FDG-PET-CT showed inﬂammation of the left
hip consistent with bursitis. We elected to follow the
patient; however, she was lost to follow-up.
T. Guggi:
Two years later, the patient was examined in our orthopedic
clinic for chronic left hip pain and muscle tenderness that
had persisted after the replacement of a fractured ceramic
head 3 years earlier. Radiography of the left hip revealed
what appeared to be metallic debris around the prosthesis
(Fig. 1). Consequently, the patient underwent revision of
the prosthesis. After removal of the cup and the deteriorated
metal head, the site was thoroughly debrided. A new cup
with a cross-linked polyethylene insert was implanted, and
a ceramic head with metal head adapter replaced the
removed metal head. The original stem was left in place.
On inspection at the time of surgery, the retrieved metal
head was worn down (Fig. 2), and there was a signiﬁcant
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amount of metallic debris surrounding the prosthesis
(Fig. 3). A blood test was performed.
Dr. Byber:
The blood test was an assay for serum cobalt. This revealed
an extremely elevated serum cobalt level of 6975 nmol/L
(normal: , 17 nmol/L), so that a diagnosis of cobalt neu-
rotoxicity was made. After surgery, cobalt levels exponen-
tially dropped to 1220 nmol/L within 40 days and to 136
nmol/L within a year, approaching the reference value of
119 nmol/L for patients with metal implants. This decrease
corresponded well to the known toxicokinetics of the metal
(1), consistent with the hypothesis that the defective pros-
thesis was the cause for the elevated cobalt level.
Final Diagnosis
Cobalt neurotoxicity from abraded metallic hip prosthesis.
Dr. Weber:
After removal of the prosthesis, the patient’s hip pain slowly
improved such that she was able to walk without discom-
fort. Her hearing, which had been slowly worsening while
the damaged prosthesis was in place, also improved (Fig. 4).
Unfortunately, her visual acuity did not improve remaining
ﬁnger counting in each eye.
Dr. Weber and Dr. Landau:
In our patient’s case, cobalt neurotoxicity caused devastating
visual loss accompanied by a dramatic deterioration of the
patient’s general condition triggered by a mechanical orthope-
dic problem. Over the last few years, reports of cobalt toxicity
related to hip implants have attracted increasing medical atten-
tion (2,3) as exempliﬁed in the television program “House”
(4). In terms of visual loss, case reports suggest that cobalt
poisoning may induce toxic effects in both retinal ganglion
cells and optic nerve axons (5,6). In our patient, the retinop-
athy was the cardinal symptom, whereas the optic neuropathy
only became apparent on follow-up. The toxicity seems to be
caused primarily through interaction of free Co(II) ions with
various metabolic processes (1). Interestingly, cobalt chloride
has been used as an hypoxia-mimicking agent in a murine
model of retinal photoreceptor cell degeneration (7).
Cobalt alloys have been widely used as implant materials
for more than 80 years due to their high speciﬁc strength.
Rarely, patients with metal-containing prostheses develop
metallosis, a local reaction of soft tissue surrounding the
implant that is characterized by the formation of a black-
FIG. 2. A. Worn-down CoCrMo metal head of the implanted
hip prosthesis compared with a new metal head (B), of the
same type. C. Worn-down polyethylene inlay with ceramic
particles imprinted in the cavity. D. Imprinted ceramic
splinters on the polyethylene inlay in the area indicated in
(C), creating an abrasive surface.
FIG. 3. Surgical site during revision of the left hip reveals
signiﬁcant metallic debris around the prosthesis.
FIG. 1. A. Radiology of the left hip shows a fractured
ceramic head (arrowhead) prompting revision of the pros-
thesis. B. During revision, the ceramic head was replaced
with a CoCrMo metal head (arrow) and a new polyethylene
liner (arrowhead). C. Radiography obtained for chronic hip
pain 3 years later reveals a worn-down metal head (black
arrowhead) with radio-opaque debris (white arrowheads).
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stained “pseudotumor” (8). In our case, the circumstances
leading to the toxic metallosis in the hip were explained by
the sequence of implants used (9) (Fig. 1). Initially, the hip
prosthesis was revised because of a fracture of the ceramic
femoral head (10). The ceramic head was replaced with a metal
head paired with a polyethylene inlay. Subsequently, ﬁne
ceramic particles left behind from the broken head adhered
to the polyethylene inlay and grinded down the new metal
head like a grindstone (Fig. 2 and Supplemental Digital
Content, Fig. E1, http://links.lww.com/WNO/A132). The
combination of incompatible implants violated a major rule
for orthopedic surgeons: never mix but always match ortho-
pedic components (11).
In hindsight, the deterioration of the patient’s general
condition, including many of her varied symptoms and
signs, were attributable to cobalt toxicity (1). The patient
not only experienced vision loss but also had both hearing
impairment and imbalance, both of which improved after
replacement of the prosthesis (Figs. 4 and 5). Although the
patient was never formally tested, her acral paresthesias may
have been due to a cobalt-induced polyneuropathy.
Two helpful laboratory signs of cobalt toxicity are
polycythemia and hypothyroidism, both of which were
present in our patient (although the hypothyroidism may
have been related solely to her previous thyroidectomy).
Polycythemia seems to be a particularly sensitive laboratory
parameter for this condition (8), as it is rarely present other-
wise in elderly patients with hip implants. Therefore, it may
be helpful to test for polycythemia in patients with cobalt-
containing implants.
Neurological complications from elevated cobalt levels in
patients with orthopedic implants are rare. In previous
reports (5,6), cobalt concentrations varied between 2074
nmol/L (serum measurements) and 10,625 nmol/L (whole
blood measurements). Cobalt concentrations can be mea-
sured in serum or in whole blood; however, in patients with
long-term exposure, the serum and blood cobalt concentra-
tions will be dissimilar, as the metal ions are incorporated
into the red blood cells (8). Therefore, whole blood meas-
urements should be performed in such cases, as they are
more representative of the actual cobalt level.
Our patient had a hypertrophic cardiomyopathy associ-
ated with congestive heart failure and a pericardial effusion.
Two years after the initial left hip revision, she had
undergone a muscle biopsy from the right ventricle that
showed cardiomyocyte degeneration and atrophy as well as
FIG. 4. Sequential audiograms show severe bilateral hearing loss with some recovery after replacement of hip prosthesis.
Hearing loss 24 months before left hip revision: right = 7%, left = 9%; hearing loss 18 months after left hip revision: right =
61% left = 66%; hearing loss 9 months after replacement of left hip prosthesis right = 47%, left = 28% (results according to
Current Procedural Terminology of the American Medical Association).
FIG. 5. Video head impulse test obtained 1.5 years after replacement of left hip prosthesis demonstrates bilaterally reduced
vestibulo-ocular reﬂex gains (normal gain .0.8) with compensatory catch-up saccades (purple spikes) in response to head
rotations to either side indicating involvement of the vestibular system.
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mild ﬁbrosis (Fig. 6). As these ﬁndings were nonspeciﬁc
(12), the suspicion of cobalt cardiac toxicity was not raised
at that time; however, in retrospect, it, too, was caused by
cobalt toxicity. The peculiar cobalt-induced cardiomyopa-
thy observed in our patient ﬁrst came to medical attention
as “Quebec beer drinker’s cardiomyopathy” (13). In 1965,
the addition of cobalt sulfate as a foam stabilizer in beer
triggered an epidemic of 48 cases of cardiomyopathy asso-
ciated with acute congestive heart failure within 9 months.
The epidemic only affected heavy beer drinkers (3–6 L/d) of
a particular brand and individuals with poor nutritional
status. Interestingly, in this acute setting with a mortality
of 40%, visual loss did not occur or perhaps simply was
overlooked under these dramatic circumstances (14).
Recovery of vision has been reported in cobalt ocular
toxicity after a decrease in ion concentration (15). Although
cobalt levels dropped rapidly during the months after hip
revision in our patient, her vision did not improve and optic
atrophy developed. The patient’s course thus suggests that,
as in other cases of toxic retinopathy or optic neuropathy,
the effects may be irreversible when toxicity is severe and
longstanding. However, improvement of her hearing, along
with the recovery of her general health, is consistent with
cobalt intoxication.
CONCLUSIONS
Through a chain of unfortunate circumstances, a mechanical
orthopedic problem turned into a devastating visual loss in
this case. Given the high prevalence of hip implants, every
neuro-ophthalmologist should keep cobalt neurotoxicity
in mind and ask patients with obscure visual loss about
hip replacements. If cobalt intoxication is suspected,
measurements of cobalt concentration should be prompted.
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FIG. 6. Myocardial biopsy performed 2 years after left hip revision. A. There is myocyte degeneration and atrophy (arrows)
and necrotic myocytes with vacuolation of the cytoplasm (asterisks) consistent with cardiomyopathy (hematoxylin & eosin). B.
Myocardial ﬁbrosis (arrows) is also present (elastica van Gieson). Additional stainings showed no signs of storage disease or
amyloidosis (not shown). The ﬁndings are not speciﬁc but consistent with cobalt cardiotoxicity.
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